These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 9595131)

  • 1. Impact of immunosuppression on coronary endothelial function after cardiac transplantation.
    Weis M; Wildhirt SM; Schulze C; Pehlivanli S; Meiser BM; Uberfuhr P; von Scheidt W
    Transplant Proc; 1998 May; 30(3):871-2. PubMed ID: 9595131
    [No Abstract]   [Full Text] [Related]  

  • 2. Tacrolimus (FK 506) in clinical cardiac transplantation: a five-year experience.
    Pham SM; Kormos RL; Kawai A; Murali S; Hattler BG; Demetris AJ; Griffith BP
    Transplant Proc; 1996 Apr; 28(2):1002-4. PubMed ID: 8623208
    [No Abstract]   [Full Text] [Related]  

  • 3. Primary immunosuppression with tacrolimus and mycophenolate mofetil versus cyclosporine and azathioprine in heart transplant recipients.
    Teebken OE; Strüber M; Harringer W; Pichlmaier MA; Haverich A
    Transplant Proc; 2002 Jun; 34(4):1265-8. PubMed ID: 12072335
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical outcomes associated with conversion to tacrolimus-based immunosuppression in pediatric cardiac transplantation.
    Walker RE; McCrindle BW; Coles JG; West LJ
    Transplant Proc; 1998 Jun; 30(4):1116-7. PubMed ID: 9636452
    [No Abstract]   [Full Text] [Related]  

  • 5. Twelve years of cyclosporine in pediatric heart transplantation: what is the future?
    Parisi F; Abbattista AD; Squitieri C; Vinciguerra G; La Vigna G; Di Donato R; Catena G
    Transplant Proc; 1998 Aug; 30(5):1967-8. PubMed ID: 9723355
    [No Abstract]   [Full Text] [Related]  

  • 6. Improved survival after lung transplantation in patients treated with tacrolimus/mycophenolate mofetil as compared with cyclosporine/azathioprine.
    Izbicki G; Shitrit D; Aravot D; Sulkes J; Saute M; Sahar G; Kramer MR
    Transplant Proc; 2002 Dec; 34(8):3258-9. PubMed ID: 12493439
    [No Abstract]   [Full Text] [Related]  

  • 7. Tacrolimus-based triple-drug immunosuppression minimizes serum lipid elevations in pediatric cardiac transplant recipients.
    Penson MG; Winter WE; Fricker FJ; Harker K; Kahler DA; Kubilis PS; Schowengerdt KO
    J Heart Lung Transplant; 1999 Jul; 18(7):707-13. PubMed ID: 10452348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term persistence of lung function abnormalities after heart transplantation.
    Ewert R; Walde T; Bettmann M; Wensel R; Bauer U; Kleber FX; Hetzer R
    Transplant Proc; 1998 Aug; 30(5):1889-91. PubMed ID: 9723322
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of tacrolimus and cyclosporine on the coronary microcirculation after heart transplantation: a prospective study with serial intracoronary flow measurements.
    Rieber J; Klauss V; König A; Henneke KH; Spes C; Regar E; Werner F; Meiser B; Reichart B; Theisen K; Mudra H
    Transplant Proc; 1998 Jun; 30(4):1098-9. PubMed ID: 9636446
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunosuppression switch in pediatric heart transplant recipients: cyclosporine to FK 506.
    Swenson JM; Fricker FJ; Armitage JM
    J Am Coll Cardiol; 1995 Apr; 25(5):1183-8. PubMed ID: 7534779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modern application for an old compound: 8-methoxypsoralen for photochemotherapy after heart transplantation.
    Meiser BM; Kur F; Uberfuhr P; Reichenspurner H; Kreuzer E; Reichart B
    Transplant Proc; 1993 Dec; 25(6):3307-8. PubMed ID: 8266554
    [No Abstract]   [Full Text] [Related]  

  • 12. Retransplantation for recurrent hepatitis C following tacrolimus or cyclosporine immunosuppression.
    Ghobrial RM; Colquhoun S; Rosen H; Hollis P; Ponthieux S; Pakrasi A; Farmer DG; Markman JF; Markowitz J; Drazan K; Yersiz H; Singer J; Stribling R; Arnout W; Holt CD; Goss J; Imagawa D; Seu P; Goldstein LI; Shackleton CR; Martin P; Busuttil RW
    Transplant Proc; 1998 Jun; 30(4):1470-1. PubMed ID: 9636597
    [No Abstract]   [Full Text] [Related]  

  • 13. Coronary endothelial vasomotor function and vascular remodeling in heart transplant recipients randomized for tacrolimus or cyclosporine immunosuppression.
    Petrakopoulou P; Anthopoulou L; Muscholl M; Klauss V; von Scheidt W; Uberfuhr P; Meiser BM; Reichart B; Weis M
    J Am Coll Cardiol; 2006 Apr; 47(8):1622-9. PubMed ID: 16631000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histopathological findings in heart transplant patients under tacrolimus-mycophenolate mofetil versus cyclosporine microemulsion-azathioprine.
    Sgrosso JL; Ferrer J; Araujo G; Romeo L; Parisi C; Vázquez MC
    Transplant Proc; 2002 Feb; 34(1):115-6. PubMed ID: 11959214
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical trial of FK506 in heart transplant patients in Taiwan: report of 7 cases with immunosuppression switch from cyclosporine to FK506.
    Ko WJ; Chou NK; Chen YS; Hsu RB; Wang SS; Chu SH
    Transplant Proc; 1998 Nov; 30(7):3339-41. PubMed ID: 9838474
    [No Abstract]   [Full Text] [Related]  

  • 16. Medium-term outcome of tacrolimus immunosuppression following rejection or graft dysfunction in heart transplant patients.
    Marcus N; Khaghani A; Burke M; Yacoub M; Banner N
    Transplant Proc; 1998 Jun; 30(4):1134-5. PubMed ID: 9636460
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of immunosuppression and pretransplant splenectomy in newborn cardiac xenograft survival.
    Xu H; Gundry SR; Hancock WW; Izutani H; Zuppan CW; Bailey LL
    Transplant Proc; 1998 Jun; 30(4):1084. PubMed ID: 9636440
    [No Abstract]   [Full Text] [Related]  

  • 18. Standard cyclosporine A-based versus completely steroid-free FK506-based immunosuppression after liver transplantation.
    Pirenne J; Aerts R; Koshiba T; Van Gelder F; Roskams T; Nevens F; Fevery J
    Transplant Proc; 2001; 33(1-2):1505. PubMed ID: 11267396
    [No Abstract]   [Full Text] [Related]  

  • 19. Risks and benefits of withdrawing cyclosporine from the long-term immunosuppression regimen of heart and heart-lung transplant recipients.
    Walker S; Habib S; Thompson D; Khaghani A; Yacoub M; Banner N
    Transplant Proc; 1998 Jun; 30(4):1149-51. PubMed ID: 9636465
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunosuppression with calcineurin inhibitors and polyclonal antibodies in liver transplantation.
    Rafecas A; Lladó L; Albiol MT; Ramos E; Torras J; Fabregat J; Lama C; Busquets J; Ibáñez L; Figueras J; Jaurrieta E
    Transplant Proc; 2002 Feb; 34(1):107. PubMed ID: 11959209
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.